Amelioration of type II collagen induced arthritis in rats by treatment with sodium diethyldithiocarbamate

Journal of Rheumatology

Volumn 26, Issue 6, 1999, Pages 1352-1358

  Voll, Reinhard E ^a   Mikulowska, Anna ^b   Kalden, Joachim R ^b   Holmdahl, Rikard ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b NONE

Author keywords

Collagen induced arthritis; Disulfiram; Ditiocarb; Inflammation; NF B; Rheumatoid arthritis

Indexed keywords

COLLAGEN TYPE 2; CYTOKINE; DIETHYLDITHIOCARBAMIC ACID; DISULFIRAM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; FEMALE; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032995989     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol 1994;12:141-79.
2. Mueller JM, Ziegler-Heitbrock HWL, Baeuerle PA. Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiol 1993; 187:3-5.
3. Feldman M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
4. Kang S-M, Tran A-S, Grilli M, Lenardo MJ. NF-κB subunit regulation in nontransformed CD4+ T lymphocytes. Science 1992;256:1452-5.
5. Geller DA, Nussler AK, Di Silvio M, et al. Cytokines, endotoxin and glucocorticoids regulate the expression of inducible nitrous oxide synthase in hepatocytes. Proc Natl Acad Sci USA 1993;90:522-6.
6. Schindler U, Baichwal VR. Three NF-κB binding sites in the human E-selectin gene required for maximal tumor necrosis factor α-induced expression. Mol Cell Biol 1994;14:5820-31.
7. Voraberger G, Schafer R, Stratowa C. Cloning of the human gene for intercellular adhesion molecule 1 and analysis of its 5′-regulatory region. J Immunol 1991;147:2777-86.
8. Neish AS, Williams AJ, Palmer HJ, Whitley MZ, Collins T. Functional analysis of the human vascular cell adhesion molecule I promoter. J Exp Med 1992;176:1583-93.
9. Schreck R, Meier B, Männel DN, Dröge W, Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor κB activation in intact cells. J Exp Med 1992;175:1181-94.
10. Ziegler-Heitbrock HWL, Sternsdorf C, Liese J, et al. Pyrrolidine dithiocarbamate inhibits NF-κB mobilization and TNF production in human monocytes. J Immunol 1993;151:6986-93.
11. Ferran C, Millan MT, Csizmadia V, et al. Inhibition of NF-κB by pyrrolidine dithiocarbamate blocks endothelial cell activation. Biochem Biophys Res Commun 1995;214:212-23.
12. Sunderman FW. Use of sodium dithiocarbamate in the treatment of nickel carbonyl poisoning. Ann Clin Lab Sci 1990;20:12-21.
13. Mossalayi MD, Descombe JJ, Musset M, Tanzer J, Goube de Laforest P. In vitro effects of sodium diethyldithiocarbamate (Imuthiol) on human T lymphocytes. Int J Immunopharmacol 1986;8:841-4.
14. Bruley-Rosset M, Vergnon I, Renoux G. Influences of sodium diethyldithiocarbamate (DTC, Imuthiol) on T-cell defective responses of aged BALB/c mice. Int J Immunopharmacol 1986;8:287-97.
15. Hersh EM, Brewton G, Abrams D, et al. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. JAMA 1991;265:1538-44.
16. Lang JM, Touraine JL, Livrozet JM, et al. The HIV87 Study Group. Multicenter, randomized placebo-controlled study of ditiocarb (Imuthiol) in human immunodeficiency virus-infected asymptomatic and minimally symptomatic patients. AIDS Res Hum Retroviruses 1993;9:83-9.
17. Awni WM, Hoff JV, Shapiro BE, Halstenson CE. A dose-ranging pharmacokinetics study of sodium diethyldithiocarbamate in normal healthy volunteers. J Clin Pharmacol 1994;34:1183-90.
18. Bodenner DL, Dedon PC, Keng PC, Katz JC, Borch RF. Selective protection against cis-diaminedichloroplatinum(II) induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate. Cancer Res 1986;46:2751-5.
19. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
20. Handel ML, McMorrow LB, Gravellese EM. Nuclear factor-κB in rheumatoid synovium: localization of p50 and p65. Arthritis Rheum 1995;38:1762-70.
21. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977;77:857-68.
22. Trentham DE. Collagen arthritis as a relevant model for rheumatoid arthritis: evidence pro and con. Arthritis Rheum 1982;25:911-6.
23. Holmdahl R, Andersson M, Goldschmidt TJ, Gustafsson K, Jansson L, Mo JA. Type II collagen autoimmunity in animals and provocations leading to arthritis. Immunol Rev 1990;118:193-232.
24. Miller EJ. Structural studies on cartilage collagen employing limited cleavage and solubilization with pepsin. Biochemistry 1972;11:4903-9.
25. Larsson P, Holmdahl R. Oestrogen-induced suppression of collagen arthritis. II. Treatment of rats suppresses development of arthritis but does not affect anti-type II collagen humoral response. Scand J Immunol 1987;26:579-83.
26. Andersen MP. Lack of bioequivalence between disulfiram formulations. Exemplified by a tablet/effervescent tablet study. Acta Psychiatr Scand 1992;86:31-5.
27. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994;265:956-9.
28. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of IκB-α in mediation of immunosuppression by glucosteroids. Science 1995;270:283-6.
29. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995; 270:286-90.
30. Yang J-P, Merin JP, Nakano T, Kato T, Kitade Y, Okamoto T. Inhibition of the DNA-binding activity of NF-κB by gold compounds in vitro. FEBS 1995;361:89-96.
31. Liu SF, Ye X, Malik AB. In vivo inhibition of nuclear factor-κB activation prevents inducible nitric oxide synthase expression and systemic hypotension in a rat model of septic shock. J Immunol 1997;159:3976-83.
32. Nemeth ZH, Hasko G, Vizi ES. Pyrrolidine dithiocarbamate augments IL-10, inhibits TNF-α, MIP-1α, IL-12, and nitric oxide production and protects from the lethal effect of endotoxin. Shock 1998;10:49-53.
33. Martinez-Martinez S, Gomez del Arco P, Armesilla AL, et al. Blockade of T-cell activation by dithiocarbamates involves a novel mechanism of inhibition of nuclear factor of activated T cells. Mol Cell Biol 1997;17:6437-47.
34. Sunderman FW, Paynter OE, George RB. The effects of protracted administration of the chelating agent, sodium diethyldithiocarbamate (Dithiocarb). Am J Med Sci 1967; 254:46-56.
35. Qazi R, Chang AYC, Borch RF, et al. Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a chemoprotector from toxic effects of cisplatin. J Natl Cancer Inst 1988;80:1486-8.
36. Borch RF, Markman M. Biochemical modulation of cisplatin toxicity. Pharmac Ther 1989;41:371-80.
37. Navikas V, Link H. Review: Cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 1996;45:322-33.
38. Scappaticci B, Soubeyrand J, Rousseau-Tsangaris M, Desage M, Brazier JL. Determination of sodium diethyldithiocarbamate (Imuthiol) and its S-methyl metabolite by gas chromatography-mass spectrometry. Use of deuteromethyl iodide derivatization. J Chromatography 1990;334:57-66.